Trial
NCT04239092
9-ING-41 in Pediatric Patients With Refractory Malignancies.
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
Actuate Therapeutics Inc.
Collaborators
—
Condition
Refractory Cancer
Intervention
9-ING-41
Why stopped
The decision to conclude study was made to optimize the clinical study design and protocol to further evaluate the safety profile of elraglusib (9-ING-41) in pediatric and adult patients with refractory Ewings Sarcoma.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-07-17